Prostate-specific antigen (PSA), a glycoprotein almost entirely secreted by the prostate gland, is considered to be one of the most reliable clinical biomarkers for the diagnosis, screening, and risk prediction of prostate cancer, and it was the first tumor biomarker approved by the Food and Drug Administration (FDA) [3, 4]. This evidence concerns the gene KLK3 and neoplasm.